Activation of the contact system and fibrinolysis in autoimmune acquired angioedema: a rationale for prophylactic use of tranexamic acid.
C1-inhibitor deficiency results in bouts of mucocutaneous edema and may be inherited (hereditary angioedema) or acquired (acquired angioedema [AAE]). The two forms have the same clinical picture but differ in the response to treatment. Prophylaxis with antifibrinolytic agents produces better results in the acquired form than in the inherited form, in which androgen derivatives are more effective. It is hypothesized that activation of the contact and fibrinolytic systems is involved in the pathogenesis of attacks. We evaluated these two systems in plasma from eight patients with AAE and anti-C1-inhibitor autoantibodies (autoimmune AAE) by measuring the cleavage of high molecular weight kininogen and the complexes formed by plasmin and its inhibitor alpha 2-antiplasmin. We also measured complement parameters, autoantibody titer, and cleaved C1-inhibitor (relative molecular mass = 96,000), because autoantibodies to C1-inhibitor are known to facilitate its cleavage by proteases. Plasma was obtained from patients in remission, during prophylactic treatment with the antifibrinolytic agent tranexamic acid (2 to 4.5 gm/day) and also from two patients during acute attacks of edema. Levels of cleaved high molecular weight kininogen and antiplasmin-plasmin complexes in patients with AAE were both higher in basal conditions, during treatment, and during acute attacks than those in normal subjects (p < 0.001). The cleaved inactive form of C1-inhibitor was also present in all patients in all three conditions. Therapy with antifibrinolytic agents reduced the frequency and intensity of symptoms without significantly changing any of the biochemical parameters.(ABSTRACT TRUNCATED AT 250 WORDS)
Cugno
M
M
Institute of Internal Medicine, University of Milan, Italy.
Cicardi
M
M
Agostoni
A
A
D000208:Acute Disease; D000368:Aged; D000799:Angioedema / Q000097:blood / Q000276:immunology* / Q000517:prevention & control*; D001323:Autoantibodies / Q000097:blood; D001327:Autoimmune Diseases / Q000097:blood / Q000276:immunology* / Q000517:prevention & control*; D003174:Complement C1 Inactivator Proteins / Q000172:deficiency / Q000276:immunology; D003165:Complement System Proteins / Q000032:analysis; D005260:Female; D005342:Fibrinolysis / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D014148:Tranexamic Acid / Q000008:administration & dosage*
D001323:Autoantibodies; D003174:Complement C1 Inactivator Proteins; D014148:Tranexamic Acid; D003165:Complement System Proteins